4.6 Article

Multiple ETS Factors Participate in the Transcriptional Control of TERT Mutant Promoter in Thyroid Cancers

Related references

Note: Only part of the references are listed.
Article Oncology

Pan-Genomic Sequencing Reveals Actionable CDKN2A/2B Deletions and Kataegis in Anaplastic Thyroid Carcinoma

Adam Stenman et al.

Summary: Anaplastic thyroid carcinoma is a deadly tumor with limited treatment options once it spreads. Research found genetic abnormalities in the patients that may respond to CDK inhibitors, as well as a phenomenon called kataegis, which could be therapeutically relevant.

CANCERS (2021)

Article Multidisciplinary Sciences

Analyses of non-coding somatic drivers in 2,658 cancer whole genomes

Esther Rheinbay et al.

NATURE (2020)

Article Biochemistry & Molecular Biology

GABPA inhibits invasion/metastasis in papillary thyroid carcinoma by regulating DICER1 expression

Xiaotian Yuan et al.

ONCOGENE (2019)

Article Oncology

Spectrum of TERT promoter mutations and mechanisms of activation in thyroid cancer

Federica Panebianco et al.

CANCER MEDICINE (2019)

Article Multidisciplinary Sciences

Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer

Rengyun Liu et al.

NATURE COMMUNICATIONS (2018)

Article Medicine, Research & Experimental

Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers

Inigo Lancia et al.

JOURNAL OF CLINICAL INVESTIGATION (2016)

Article Oncology

Long-Range Chromatin Interactions Drive Mutant TERT Promoter Activation

Semih Can Akincilar et al.

CANCER DISCOVERY (2016)

Article Biochemistry & Molecular Biology

Integrated Genomic Characterization of Papillary Thyroid Carcinoma

Nishant Agrawal et al.

Article Endocrinology & Metabolism

TERT Promoter Mutations Are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas

Miguel Melo et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)

Article Oncology

Highly prevalent TERT promoter mutations in aggressive thyroid cancers

Xiaoli Liu et al.

ENDOCRINE-RELATED CANCER (2013)

Article Endocrinology & Metabolism

Frequent Somatic TERT Promoter Mutations in Thyroid Cancer: Higher Prevalence in Advanced Forms of the Disease

Inigo Landa et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)

Article Multidisciplinary Sciences

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

Patrick J. Killela et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)

Article Multidisciplinary Sciences

TERT Promoter Mutations in Familial and Sporadic Melanoma

Susanne Horn et al.

SCIENCE (2013)

Article Multidisciplinary Sciences

Highly Recurrent TERT Promoter Mutations in Human Melanoma

Franklin W. Huang et al.

SCIENCE (2013)

Review Biochemistry & Molecular Biology

Genomic and Biochemical Insights into the Specificity of ETS Transcription Factors

Peter C. Hollenhorst et al.

ANNUAL REVIEW OF BIOCHEMISTRY, VOL 80 (2011)

Article Biochemistry & Molecular Biology

Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo

Gong-Hong Wei et al.

EMBO JOURNAL (2010)

Article Multidisciplinary Sciences

V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway

Christine A. Pratilas et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)

Article Biochemistry & Molecular Biology

Ets2 maintains hTERT gene expression and breast cancer cell proliferation by interacting with c-Myc

Dakang Xu et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2008)